Strategic License Agreement - Additional Information (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2017 USD ($)	Dec. 31, 2021 USD ($) LicenseAgreement $ / shares € / shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 18,739	$ 0	$ 0
Reimbursement		3,000
Deferred revenue		2,359	0
Contract liabilities		0	0	0
Contract assets		0	0	0
PEACE Trial | BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 6,700
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial		50.00%
Upfront payment		$ 21,500
Transaction price		23,300
Allocation price net		12,000
Immedica Pharma AB | PEACE Trial | BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price		7,200
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price		$ 4,100
License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date		2013-12
Revenue recognized		$ 12,000	0	0
Number of license agreements | LicenseAgreement		2
Maximum future contingent license payment	$ 6,400
Aggregate potential milestone payments for receipt of regulatory approval	5,000
Aggregate potential milestone payments for final regulatory approval of second indication	$ 500
Annual license fees paid		$ 100	100	$ 100
License Agreements | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Rate of revenue share	25.00%
License Agreements | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Rate of revenue share	6.50%
License Agreements | Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date		2021-03
Revenue recognized		$ 12,000
Deferred revenue		3,600
Deferred revenue		2,400	$ 0
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non refundable payment received		$ 21,500
Percentage of payment for cost incurred in PIP trial		50.00%
Additional upfront payment to be received		$ 125,000
Rate of revenue share		25.00%
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Costs incurred in performing PIP the trial		$ 1,800
Milestone payments exchange rate | € / shares		1.00
Immedica Pharma AB | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments exchange rate | $ / shares		1.13